Industrial Strategy for Secure Medicines Manufacturing

Executive argument

Domestic manufacturing contributes to security only when facilities, skills, inputs, quality systems and commercial incentives remain operational.

Capability choices

Strategy should distinguish products requiring sovereign assurance, capabilities secured through trusted alliances and commodities suited to diversified sourcing.

Policy instruments

Long-term procurement, challenge funds, regulatory support, shared infrastructure and workforce investment can improve viability.

Conclusion

The test is not facilities announced but the system's ability to supply priority medicines through stress.

Evidence notes and limits

This perspective proposes an analytical framing; it does not report an empirical study, systematic review or validated measurement. The sources below provide policy context. MSI’s recommendations remain its own interpretation and do not imply source endorsement.

Selected references

• DHSC and NHS England (2025), Managing a robust and resilient supply of medicines · accessed 13 October 2026
• DHSC (2025), Accompanying data pack · accessed 13 October 2026

Authorship, interests and review

Institutional authorship: Medicines Security Institute. Enquiries and corrections are overseen by the Founder & Executive Director. Independent peer review is not claimed. This record has no verified publication-specific funding or conflict disclosure; readers may request clarification through the research office.

Read the expanded full working-paper manuscript (October 2026 draft) →

Version record

September 2026: introductory record. 13 October 2026: clarified publication type, aligned downloadable text, added source notes and review limits. Substantive research expansion will be separately dated and reviewed.